Pembrolizumab plus chemotherapy versus chemotherapy alone fo...

🤖 Plain-English Summary

This research explores Pembrolizumab plus chemotherapy versus chemotherapy alone fo..., contributing new insights to the field of Medicine & Biology.

🔑 Key Findings

Research demonstrates significant advances in patient outcome data
Study provides new evidence regarding clinical efficacy results
Findings open new directions for biological mechanism insights

💡 Why This Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

Read the full paper
Access the original peer-reviewed research via OpenAlex.

View on DOI ↗

📜 Copyright Notice: This page shows only metadata (title, authors, journal, date) and an original AI-generated summary. No abstract or full article text is copied. The original research is the intellectual property of its authors and publisher. ScienceTrace does not reproduce copyrighted content.

← More Medicine & Biology All Research Articles

📋 Article Details

Category	🧬 Medicine & Biology
Published	Aug 01, 2021
Journal	The Lancet
Authors	Jong‐Mu Sun, Lin Shen, Manish A. Shah, Peter C. Enzinger, Antoine Adenis
DOI	10.1016/s0140-6736(21)01234-4
Citations	1,573
Source	OpenAlex

🗂️ Research Categories

🤖 Artificial Intelligence 🧬 Medicine & Biology ⚛️ Physics & Space Science ⚙️ Engineering & Technology ∑ Mathematics

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

🤖 Plain-English Summary

🔑 Key Findings

💡 Why This Matters

📋 Article Details

🗂️ Research Categories

🔗 Related Resources

More 🧬 Medicine & Biology Research